Novavax Inc NVAX.O said on Friday it expects to provide a COVID-19 vaccine targeting Omicron in the fourth quarter as it accelerates the development of shots to protect against the BA.4 and BA.5 subvariants.
The U.S. FDA on Thursday recommended COVID-19 vaccine manufacturers change the design of their booster shots beginning this fall to include components tailored to combat the currently dominant Omicron BA.4 and BA.5 subvariants.
- Kidney in a box: Advancements in transplant technology allows for quicker recovery
- Sections of B.C.’s involuntary care rules found unconstitutional
- Cat with rabies prompts 3 people to receive emergency treatment in Montreal area
- Cyberattacks on water systems are growing in the U.S. — is Iran involved?
-
![]()
Health Matters: Health Canada grants injunction against unauthorized peptide producer -
![]()
Congo struggles to contain fastest-ever Ebola outbreak, as death toll passes 1,500 -
![]()
Hemodialysis lab in southern Alberta receives multi-million-dollar boost -
![]()
Kingston woman marks 106th donation as Canada’s blood supply drops
Novavax expects additional preclinical data on shots tailored against the fast-spreading Omicron subvariants in late summer or fall.
The company’s vaccine, based on an earlier strain of the virus, has not yet been authorized in the United States and is currently under U.S. Food and Drug Administration review.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Shounak Dasgupta)
Comments
Want to discuss? Please read our Commenting Policy first.